1st human trial to test LBL-034 for hard-to-treat myeloma in US, China
Nanjing Leads Biolabs is planning to launch a first-in-human clinical trial to test LBL-034, an antibody-based therapy designed to trigger the immune system to…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Myeloma cells in lab, mice killed with nanoparticle-delivered RNA
Researchers at Tel Aviv University in Israel have developed a new nanoparticle system that can deliver RNA-based therapies designed to kill myeloma cells in…
2 Janssen therapies for RRMM earn positive opinion from EU committee
A European Medicines Agency committee has recommended that one antibody-based cancer therapy from Janssen Pharmaceuticals be approved for the treatment of relapsed and refractory…
Next IMF Patient and Family Seminar slated for Aug. 18-19 in LA
The International Myeloma Foundation (IMF) will host its second in-person Patient and Family Seminar of the year on Aug. 18-19 in Los Angeles.
Study shows less hospital time for outpatient stem cell transplants
Multiple myeloma patients undergoing a stem cell transplant in an outpatient setting spent about a week less in the hospital than those undergoing the…
FDA puts CART-ddBCMA Phase 2 trial on hold after patient’s death
The U.S. Food and Drug Administration (FDA) has placed a hold on clinical testing of CART-ddBCMA, a cell therapy that Arcellx and Kite…
